FunPep is a public, late clinical-stage therapeutics company that has developed a functional peptide and antibody-inducing peptide platform. Antibody-inducing peptides are unique compounds that produce antibodies in vivo by administering the peptide alone. Our lead asset is licensed to Shionogi, with another clinical asset optioned to Sumitomo Pharma, and two ongoing R&D collaborations using our platform. We are seeking to partner our three pre-clinical assets and find additional R&D collaborations for our platform.
Ticker:
4881
Exchange:
Tokyo Stock Exchange Growth Market
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2013
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
FPP003
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
